Menu Search
Equities

Molecular Partners AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6ML:STU

Molecular Partners AG

Actions
  • Price (EUR)3.93
  • Today's Change0.265 / 7.24%
  • Shares traded0.00
  • 1 Year change--
  • Beta0.7272
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year Molecular Partners AG had revenues fall -29.38% from 7.04m to 4.97m, though the company grew net income from a loss of 61.98m to a smaller loss of 54.04m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-45.23%
Return on equity-51.42%
Return on investment-49.34%
More ▼

Cash flow in CHFView more

In 2024, cash reserves at Molecular Partners AG fell by 3.44m. However, Cash Flow from Investing totalled 40.49m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 59.25m for operations while cash generated from financing totalled 14.43m.
Cash flow per share-1.58
Price/Cash flow per share--
Book value per share2.55
Tangible book value per share2.55
More ▼

Balance sheet in CHFView more

Molecular Partners AG appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio9.28
Quick ratio--
Total debt/total equity0.016
Total debt/total capital0.0158
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.